Navigation Links
Akela Pharma reports results for third quarter of fiscal 2007
Date:11/9/2007

ation of the Fentanyl TAIFUN(R) Phase II trial program and the development of our product candidates.

The consolidated net loss for the third quarter of 2007 was $8.6 million, or ($0.73) per share and $23.8 million or ($2.03) per share year-to-date, compared with a consolidated net income for the former Pharma segment of $12.0 million and $0.8 million, respectively.

The Company had cash and cash equivalents as of September 30, 2007 of $15.1 million. compared with $35.3 million as of December 31, 2006.

THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC (FILE NO. 333-146684) FOR AN OFFERING OF ITS SECURITIES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS THE ISSUER HAS FILED WITH THE SEC FOR MORE COMPLETE INFORMATION ABOUT THE ISSUER AND THIS OFFERING. YOU MAY GET THESE DOCUMENTS FOR FREE BY VISITING EDGAR ON THE SEC WEB SITE AT http://WWW.SEC.GOV. ALTERNATIVELY, THE ISSUER, ANY UNDERWRITER OR ANY DEALER PARTICIPATING IN THE OFFERING WILL ARRANGE TO SEND YOU THE PROSPECTUS IF YOU REQUEST IT BY CONTACTING OPPENHEIMER AND CO. INC. AT 125 BROAD STREET, 16TH FLOOR, NEW YORK, NEW YORK 10004, ATTENTION: SYNDICATE DEPARTMENT, OR BY PHONE AT (212) 825 4341

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forwar
'/>"/>

SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... NJ (PRWEB) July 31, 2014 A cancer ... of people survive cancer and resume normal lives. This is ... Cancer Society, will affect one in seven American men but ... has a five-year survival rate of nearly 100% and a ... illness but most men diagnosed with the disease do not ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... on nine secrets that addicts don’t want others to know. ... an addict from a mile away, and totally understand what’s ... Per Wickstrom . “However, take it from me: spotting ...
(Date:7/31/2014)... In its latest blog post, Best Drug ... family close by during a stay in rehab can make ... successful, is looking at 10 tips to help drug or ... is a lifelong process, and one that former addicts and ... compromise,” commented Best Drug Rehabilitation’s CEO Per Wickstrom . ...
(Date:7/31/2014)... 31, 2014 Thanks to its ... erythritol has long been used as a medium ... and monk fruit. However consistent, dependable sourcing of ... to meet food and beverage manufacturers’ increasing needs ... has launched GMO-free ErysweetTM Erythritol. , “Erysweet ...
(Date:7/31/2014)... Arizona (PRWEB) July 31, 2014 Nuanced ... announce the launch of the Nuanced Medical website ... created for the needs of the Medical Industry. , ... products and services for medical practices to meet continuously ... regulations being the HIPAA Act (Health Insurance Portability and ...
Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Steviva Ingredients Launches Erysweet Erythritol 2Health News:Nuanced Media, HIPAA Certified Agency, Launches Medical Web Design Service Website 2
... drugs , , WEDNESDAY, June 17 (HealthDay News) -- ... invade the nervous system of patients with a blood-borne ... the development of drugs that block these molecules and ... which primarily strikes children and adolescents, the bone marrow ...
... ... has been regularly engaging its healthcare provider customers in discussions about healthcare reform, the ... technology to address short and long-term healthcare objectives. , ... Stamford, CT (Vocus) June 18, 2009 -- ...
... Today the National Multiple Sclerosis Society - Wisconsin ... 2009 Physician Appreciation Award. The recognition commends Dr. Khatri ... and his research to treat it. , , ... honored to receive this recognition," says Dr. Khatri, medical ...
... 17 PRA International, a leading Clinical Research Organization, announces ... Information Association (DIA) meeting June 21 - 25 in San ... Executive Director of Medical Affairs will make a presentation entitled ... , In addition, Dr. Starkey and other PRA medical, ...
... , Redskins Kicker Shaun Suisham,s Foursome Takes First Place , ... 23rd Annual Maryland Golf Classic presented by Capital Carpets & ... kidney disease in the Washington DC area, a region that ... The tournament took place on June 15 at the picturesque ...
... quality improvement and affordable coverage for all Americans , ... Majority Leaders Howard Baker, Tom Daschle and Bob Dole, ... today released a bipartisan, budget-neutral framework for comprehensive health ... health coverage. The Leaders, Project on the State of ...
Cached Medicine News:Health News:Taking Aim at Relapse of Leukemia in Kids 2Health News:IVANS Hit Experts Available To Discuss the Dept. of HHS Recommendation Of “Meaningful Use” and How Potential Tighter Standards Will Impact the Provider Community 2Health News:IVANS Hit Experts Available To Discuss the Dept. of HHS Recommendation Of “Meaningful Use” and How Potential Tighter Standards Will Impact the Provider Community 3Health News:Aurora Physician Recognized for Multiple Sclerosis Care 2Health News:PRA International Experts Present at the 45th Annual DIA Meeting 2Health News:National Kidney Foundation's 23rd Annual Maryland Golf Classic Raises Funds to Fight Kidney Disease 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 3Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 4
(Date:7/31/2014)... De Pfizer Clinical Research Unit (PCRU) heeft ... van Japanse komaf voor medewerking aan klinisch onderzoek. De ... één van twee onderzoekseenheden van Pfizer , een ... door de ontdekking en ontwikkeling van nieuwe medicijnen. Om ... mannen en vrouwen van Japanse komaf – leeftijd 18 ...
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... 30, 2014 The Board of Directors ... last evening expressed support for the "Pharmacists, Patient ... of Pharmacy Practitioners (JCPP).  As a JCPP member, ... two-year period to develop a scalable, viable and ... "Pharmacists are fast becoming one of the ...
Breaking Medicine Technology:Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... April 5, 2011 Danaher Corporation (NYSE: ... been promoted to Senior Vice President and Amir Aghdaei ... and Group Executive of Danaher. In his ... Danaher,s Dental segment, which includes KaVo Group and Sybron ...
... 5, 2011 Practice Fusion, the fastest growing ... $23 million Series B round of financing led ... Management and Glynn Capital Management, as well as ... round brings the company,s total funding to $30 ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2Founders Fund Leads $23 Million Practice Fusion Financing Round 2Founders Fund Leads $23 Million Practice Fusion Financing Round 3Founders Fund Leads $23 Million Practice Fusion Financing Round 4Founders Fund Leads $23 Million Practice Fusion Financing Round 5
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: